Screener
Precigen PGEN Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Precigen in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Precigen’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356090-26-000017
| (Amounts in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net decrease in cash, cash equivalents, and restricted cash | (22,754) | (23,459) |
| Cash, cash equivalents, and restricted cash | ||
| Beginning of period | 30,234 | 29,517 |
| End of period | $7,480 | $6,058 |
| Supplemental disclosure of cash flow information | ||
| Cash paid during the period for interest | $2,563 | — |
| Significant noncash activities | ||
| Accrued compensation paid in equity | $3,371 | — |
Item 1. Condensed Consolidated Financial Statements
FAQ
- What is Precigen's cash & equivalents?
- Precigen (PGEN) reported cash & equivalents of $7.48M in Q1 2026.
- How has Precigen's cash & equivalents changed year-over-year?
- Precigen's cash & equivalents increased by 23.5% year-over-year, from $6.06M to $7.48M.
- What is the long-term trend for Precigen's cash & equivalents?
- Over 5 years (2020 to 2025), Precigen's cash & equivalents has grown at a -10.4% compound annual growth rate (CAGR), from $52.25M to $30.23M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Precigen's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude